Diagnostic value of cerebrospinal fluid alpha-synuclein in dementia with Lewy body

Gériatrie et psychologie neuropsychiatrie du vieillissement
Olivier Bousiges, Frédéric Blanc

Abstract

Dementia with Lewy body (DLB) is the second most common form of dementia after Alzheimer's disease (AD), accounting for 15% to 20% of neuropathologically defined cases. Two-thirds of the patients affected are not or misdiagnosed. In this review, we evaluate the discriminatory power of cerebrospinal fluid (CSF) alpha-synuclein by focusing more specifically on differential diagnosis between DLB and AD. Alpha-synuclein assay in the CSF has an interest in the discrimination between DLB and AD but not in segregation between DLB and healthy elderly subjects. The development of biomarkers such as phospho-alpha-synuclein and oligomeric alpha-synuclein should help to reinforce this discrimination power.

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Gériatrie et psychologie neuropsychiatrie du vieillissement
Olivier Bousiges, Frédéric Blanc
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Sylvie SlaetsSebastiaan Engelborghs
Clinical Chemistry and Laboratory Medicine : CCLM
Argonde C van HartenPhilip Scheltens
International Journal of Alzheimer's Disease
Thomas LeyheWalter Maetzler
© 2022 Meta ULC. All rights reserved